BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD.
百奧賽圖(北京)醫藥科技股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2315)

INSIDE INFORMATION
ANNOUNCEMENT OF ESTIMATED ANNUAL RESULTS FOR THE YEAR 2025

This announcement is made by Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") pursuant to the disclosure obligations under Rule 13.09(2)(a) and Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The Company sets out in this announcement the financial data for the year of 2025. Such data are prepared in accordance with the China Accounting Standards for Business Enterprises and are preliminary accounting data only and have not been audited by a certified public accountant. The data set out in this announcement may differ from the final data to be disclosed in the annual report of the Company. Shareholders and investors of the Company are advised to exercise caution when dealing in the shares of the Company.

I. ESTIMATED RESULTS FOR THE PERIOD

(I) Period of estimated results

From January 1, 2025 to December 31, 2025.

(II) Estimated results

1. Based on the preliminary calculations by the finance department of the Company, it is expected that the Group's revenue for the year 2025 will be ranging from RMB1,368,808,400 to RMB1,388,808,400, representing an increase of RMB388,354,500 to RMB408,354,500 as compared with the corresponding period of last year, or a year-on-year increase of 39.61% to 41.65%.

2. It is expected that the net profit attributable to owners of the Company for the year 2025 will be ranging from RMB162,428,600 to RMB182,428,600, representing an increase of RMB128,886,800 to RMB148,886,800 as compared with the corresponding period of last year, or a year-on-year increase of 384.26% to 443.88%.

3. It is expected that the net profit attributable to owners of the Company after deducting non-recurring profit or loss for the year 2025 will be ranging from RMB104,919,300 to RMB124,919,300, representing an increase of RMB81,951,300 to RMB101,951,300 as compared with the corresponding period of last year, or a year-on-year increase of 356.81% to 443.88%.

II. RESULTS AND FINANCIAL CONDITIONS FOR THE CORRESPONDING PERIOD OF LAST YEAR

1. Revenue: RMB980,453,900.

2. Total profit: RMB42,939,600.

3. Net profit attributable to owners of the Company: RMB33,541,800.

4. Net profit attributable to owners of the Company after deducting non-recurring profit or loss: RMB22,968,000.

5. Earnings per share: RMB0.08.

III. MAIN REASONS FOR THE CHANGES IN RESULTS FOR THE PERIOD

(I) Benefiting from the continuous expansion in overseas markets coupled with the recovery and warming up of the domestic biopharmaceutical industry, the Company achieved rapid growth in revenue.

(II) The high-entry-barrier technological advantages supported the maintenance of a high gross profit of the business, while lean management initiatives further enhanced operating efficiency, enabling the rapid improvement of the Company's profitability.

IV. RISK WARNING

This estimated results announcement is based on the preliminary calculations made by the finance department of the Company based on its own professional judgment and has not been audited by a certified public accountant. There are no material uncertainties affecting the accuracy of the contents of this estimated results announcement.

V. OTHER MATTERS

The above estimated data are only preliminary accounting data. For specific and accurate financial data, please refer to the audited 2025 annual report to be officially disclosed by the Company. Investors are advised to pay attention to investment risks.

By order of the Board
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
Shen Yuelei
Chairman of the Board, Chief Executive Officer and Executive Director

Hong Kong, January 29, 2026

As at the date of this announcement, the Board comprises Dr. Shen Yuelei as chairman, chief executive officer and executive director, Dr. Ni Jian as executive director; Dr. Zhou Kexiang and Ms. Zhang Leidi as non-executive directors; Mr. Hua Fengmao, Dr. Yu Changyuan and Ms. Liang Xiaoyan as independent non-executive directors; and Ms. Li Yan as employee director.